从结构上看，钢铁、汽车以及部分医药产品此前谈判形成的特殊安排预计仍会保留，这些领域短期冲击相对有限。但除更多消费类商品和普通制造品将面临 与其他国家相同的关税环境。从威士忌到玩具等产品，过去依赖品牌和渠道优势的企业，如今不得不重新面对成本压力和市场份额的再分配。 英国政府一直把对美贸易关系当成一项重要成果对外宣传，此前双方沟通形成的框架中，英国商品进入美国市场大体适用约10%的对等关税水平，相比多数 国家处于更有利的位置，这让不少英国出口企业在价格竞争上占据一定空间。市场一度认为，在全球贸易摩擦加剧的背景下，这种相对优惠的安排将成为英 国稳定外贸的重要支撑。 然而美国方面提出将对各国普遍适用更高的关税水平，税率可能提升至15%。一旦这一方案全面执行，英国原本依赖的税率优势将明显削弱。相关机构测算 显示，在主要贸易伙伴中，英国面临的关税上调幅度可能最为明显，这意味着此前建立的竞争优势可能在短时间内被重新洗牌。 英国商界估算，若整体税率上行，对美出口成本可能增加约30亿英镑，涉及约4万家企业。对于依赖美国市场的制造商、消费品企业以及中小出口商来说， 利润空间将被明显压缩。一些企业已经开始重新评估订单结构和定价策略 ...

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABBV) with an Overweight rating. It set a price target of $275 on the stock. The firm said current consensus estimates do not fully reflect AbbVie’s operating leverage potential. In its note, Barclays added that positive results from any of the company’s proof-of-concept s ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract. ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation On February 20, Barclays started coverage of Merck & Co., Inc. (NYSE:MRK) with an Overweight rating. It set a $140 price target on the stock. The firm said the company’s 2026 will bring “first-in-class” launches and important data readouts that could shape its next phase of growth. The analyst added that Merck shares offer pote ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock. The firm said GLP-1 weight loss treatments represent a “durable structural shift,” reflecting growing confidence in the long-term demand for these therapies. The ...

Novo Nordisk Trips in the Obesity Race - Moby THE GIST Novo Nordisk just learned the hard way that in the obesity drug arms race, close is not good enough. A key head-to-head trial showed its next big shot failed to match Eli Lilly’s market leader, and investors responded by knocking about 15% off the stock in a single session. WHAT HAPPENED Novo Nordisk said its experimental once-weekly obesity injection CagriSema delivered 23% average weight loss after 84 weeks in a late stage trial. That compared with ...

Industry Overview - The pharmaceutical sector in the United States was valued at $634.32 billion in 2024 and is projected to grow to $883.97 billion by 2030, driven primarily by customized medication, which is expected to increase from $169.56 billion in 2024 to $307.04 billion by 2033 at a CAGR of 6.82% [2] - The industry has undergone significant changes due to policy shifts during Donald Trump's administration, including a "Build It Here" campaign to boost domestic manufacturing and a 100% tariff on imported brand-name medications [3] - Regulatory reforms have expedited the approval of generic and biosimilar products, contributing to a larger movement toward cost containment and pharmaceutical self-sufficiency [3] Market Challenges - The pharmaceutical industry faces risks such as the impending $350 billion global patent cliff due to the loss of market exclusivity for key medications like Keytruda and Eliquis [4] - Despite these challenges, growth is expected to be sustained by advancements in gene treatments, biologics, and artificial intelligence [4] - Analysts from Deloitte, PwC, and S&P Global Ratings predict robust credit conditions supported by substantial cash reserves and ongoing industrial innovation [4] Company Highlights - Hims & Hers Health, Inc. (NYSE:HIMS) is identified as one of the most oversold stocks, with a Relative Strength Index (RSI) of 16.68 and a price target upside of 94.39% [9] - The company announced a deal to acquire Eucalyptus for up to $1.15 billion, with plans to finance the agreement through current cash and future U.S. operating cash flows [10][11] - Hims & Hers faced backlash after attempting to launch a $49 oral semaglutide weight-loss pill, leading to a quick reversal of the offering due to regulatory concerns [12] - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is another oversold stock with an RSI of 40.53 and a price target upside of 36.79% [14] - The company reported strong financial results, with Q4 net product sales increasing by 29% year-over-year to $798.3 million and full-year sales reaching $2.83 billion [15] - INGREZZA, one of Neurocrine's products, generated $657.5 million in Q4 sales, reflecting 7% annual growth, supported by strong prescription demand [16]

Achieved 66% annual revenue growth driven by Auvelity's rapid uptake, which surpassed $500,000,000 in net sales in its third full year of launch. Attributed Auvelity's outperformance to its distinct clinical profile and fast onset of action, allowing it to grow 42% year-over-year while the broader antidepressant market remained flat. Expanded the primary care prescriber base for Auvelity, which now represents approximately one-third of all prescribers and is the fastest-growing segment. Initiated a ...

Key Takeaways FOLD reported Q4 EPS of 10 cents, missing estimates, as revenues rose 24% Y/Y to $185.2M.Amicus saw Galafold sales rise 14% and Pombiliti plus Opfolda jump 51% Y/Y at constant exchange rates.BioMarin will acquire Amicus for $14.50 per share in a $4.8B cash deal set to close in Q2 2026.Amicus Therapeutics (FOLD) reported adjusted earnings of 10 cents per share for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 13 cents. The company had reported adjusted earnings of 9 c ...

Core Viewpoint - The company announced that its weight-loss drug will be available at the same self-pay price in both single-dose vial format and multi-dose pen format, which allows for four weekly injections from a single device [1] Group 1 - The weight-loss drug will be offered in two formats: single-dose vials and multi-dose pens [1] - The multi-dose pen format enables patients to receive four weekly injections from one device [1]